- Home
- NVGS vs CMRX Comparison
NVGS vs CMRX Comparison
Compare NVGS & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVGS
- CMRX
- Stock Information
- Founded
- NVGS 1997
- CMRX 2000
- Country
- NVGS United Kingdom
- CMRX United States
- Employees
- NVGS N/A
- CMRX N/A
- Industry
- NVGS Marine Transportation
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- NVGS Consumer Discretionary
- CMRX Health Care
- Exchange
- NVGS Nasdaq
- CMRX Nasdaq
- Market Cap
- NVGS 957.8M
- CMRX 797.3M
- IPO Year
- NVGS N/A
- CMRX 2013
- Fundamental
- Price
- NVGS $13.22
- CMRX $8.52
- Analyst Decision
- NVGS Strong Buy
- CMRX Hold
- Analyst Count
- NVGS 3
- CMRX 4
- Target Price
- NVGS $22.00
- CMRX $8.51
- AVG Volume (30 Days)
- NVGS 270.7K
- CMRX 8.5M
- Earning Date
- NVGS 03-12-2025
- CMRX 03-21-2025
- Dividend Yield
- NVGS 1.51%
- CMRX N/A
- EPS Growth
- NVGS 8.18
- CMRX N/A
- EPS
- NVGS 1.19
- CMRX N/A
- Revenue
- NVGS $566,679,000.00
- CMRX $212,000.00
- Revenue This Year
- NVGS $3.48
- CMRX $2,685.38
- Revenue Next Year
- NVGS $1.14
- CMRX $1,050.23
- P/E Ratio
- NVGS $11.08
- CMRX N/A
- Revenue Growth
- NVGS 2.90
- CMRX N/A
- 52 Week Low
- NVGS $13.05
- CMRX $0.75
- 52 Week High
- NVGS $18.18
- CMRX $8.53
- Technical
- Relative Strength Index (RSI)
- NVGS 26.50
- CMRX 83.28
- Support Level
- NVGS $13.15
- CMRX $8.41
- Resistance Level
- NVGS $14.47
- CMRX $8.52
- Average True Range (ATR)
- NVGS 0.36
- CMRX 0.02
- MACD
- NVGS -0.00
- CMRX -0.15
- Stochastic Oscillator
- NVGS 11.85
- CMRX 85.72
About NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture).
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.